September 14, 2014 10:04 PM ET

Pharmaceuticals

Company Overview of Boehringer Ingelheim Pharmaceuticals, Inc.

Company Overview

Boehringer Ingelheim Pharmaceuticals, Inc. provides human prescription medicines. It offers pharmaceutical products for the treatment of lung health, cardiovascular diseases, men's prostate health, and anti-viral therapy. The company’s products include angiotensin II receptor blocker Micardis tablets for the reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients who are unable to take angiotensin-converting enzyme inhibitors; and COMBIVENT RESPIMAT (ipratropium bromide and albuterol), an inhaler for patients with chronic obstructive pulmonary disease. Its products also comprise Flibanserin, a compound for the treatment of hypoactive sexual des...

900 Ridgebury Road

Ridgefield, CT 06877-0368

United States

Founded in 1971

Phone:

203-798-9988

Fax:

203-791-6234

Key Executives for Boehringer Ingelheim Pharmaceuticals, Inc.

Executive Vice President of Sales & Marketing - Prescription Medicines Business
Director of Office of Diversity and Inclusion
Manager of Communications and Public Relations
Compensation as of Fiscal Year 2014.

Boehringer Ingelheim Pharmaceuticals, Inc. Key Developments

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company Announce Launch of Jardiance Prescription Tablets for Adults with Type 2 Diabetes in the US Stores

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company jointly announced the availability of Jardiance (empagliflozin) tablets by prescription for adults with type 2 diabetes (T2D) in Walgreens, Rite Aid, Kroger and many other chain and independent retailers in the US. According to the companies, JARDIANCE, a once-daily, 10 mg or 25 mg tablet, is a sodium glucose co-transporter-2 (SGLT2) inhibitor. JARDIANCE works by blocking the reabsorption of glucose in the kidney, increasing glucose excretion and lowering blood glucose levels in adults with type 2 diabetes who have elevated blood glucose levels. On 1 August 2014, the US Food and Drug Administration (FDA) approved JARDIANCE as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D).

FDA Approves Boehringer Ingelheim's Tiotropium Respimat for the Maintenance Treatment of COPD

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted that existing data supports approval of Boehringer Ingelheim's investigational tiotropium bromide inhalation spray for long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema and to reduce exacerbations in COPD patients. If approved by the FDA, the proposed proprietary name for tiotropium bromide inhalation spray will be Spiriva(R) Respimat(R). The Advisory Committee voted that existing data supports approval after a review of the results from eight efficacy clinical trials in which 8,700 patients were treated with tiotropium in the RESPIMAT inhaler. One of these trials, TIOSPIR(TM), the large clinical trial conducted to date in patients with COPD, collected data from more than 17,000 COPD patients from 50 countries.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Announce Approving Jardiance Tablets for Adults with Type 2 Diabetes by FDA

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the U.S. Food and Drug Administration approved Jardiance tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). JARDIANCE is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine). JARDIANCE, a once-daily, 10 mg or 25 mg tablet, is a sodium glucose co-transporter-2 (SGLT2) inhibitor. JARDIANCE works by blocking the reabsorption of glucose in the kidney, increasing glucose excretion and lowering blood glucose levels in adults with T2D who have elevated blood glucose levels. Patients should not take JARDIANCE if they have severe kidney problems or are on dialysis, or if they are allergic to empagliflozin or any ingredient in JARDIANCE. JARDIANCE can cause some people to have dehydration (the loss of body water and salt), which may lead to a drop in blood pressure, and may cause patients to feel dizzy or faint.

Similar Private Companies By Industry

Company Name Region
Heritage Consumer Products, Inc. United States
Kos Pharmaceuticals, Inc. United States
GAVIS Pharmaceuticals, LLC United States
Lifecycle Pharma Inc. United States
Synereca Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Boehringer Ingelheim Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.